Inositols: From Established Knowledge to Novel Approaches
Open accessThe DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index.
Abstract
Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to clinical approaches in ameliorating many gynecological and endocrinological diseases. Currently both myo-Ins and D-chiro-Ins are well-tolerated, effective alternative candidates to the classical insulin sensitizers, and are useful treatments in preventing and treating metabolic and reproductive disorders such as polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and male fertility disturbances, like sperm abnormalities. Moreover, besides metabolic activity, myo-Ins and D-chiro-Ins deeply influence steroidogenesis, regulating the pools of androgens and estrogens, likely in opposite ways. Given the complexity of inositol-related mechanisms of action, many of their beneficial effects are still under scrutiny. Therefore, continuing research aims to discover new emerging roles and mechanisms that can allow clinicians to tailor inositol therapy and to use it in other medical areas, hitherto unexplored. The present paper outlines the established evidence on inositols and updates on recent research, namely concerning D-chiro-Ins involvement into steroidogenesis. In particular, D-chiro-Ins mediates insulin-induced testosterone biosynthesis from ovarian thecal cells and directly affects synthesis of estrogens by modulating the expression of the aromatase enzyme. Ovaries, as well as other organs and tissues, are characterized by a specific ratio of myo-Ins to D-chiro-Ins, which ensures their healthy state and proper functionality. Altered inositol ratios may account for pathological conditions, causing an imbalance in sex hormones. Such situations usually occur in association with medical conditions, such as PCOS, or as a consequence of some pharmacological treatments. Based on the physiological role of inositols and the pathological implications of altered myo-Ins to D-chiro-Ins ratios, inositol therapy may be designed with two different aims: (1) restoring the inositol physiological ratio; (2) altering the ratio in a controlled way to achieve specific effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the secondary signaling mechanisms, inositol triphosphate (IP3) will also be released, which can be converted to free myoinositol by inositol-monophosphatase [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, DCI is an aromatase inhibitor and promotes glycogen synthase, which inhibits the conversion of androgens to estrogens, resulting in the accumulation of androgens and lack of estrogens.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in the short term, it can improve insulin levels, thus promoting SHBG production [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inositols are considered insulin sensitizers, as they modulate the members of insulin signaling pathways [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
- Retracted
Marín, I. H., Picconi, O., Laganà, A. S., Costabile, L., & Unfer, V. (2021) · PubMed · doi:10.26355/eurrev_202104_25743 · Cited by 31
Self-citationRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
(1991) · The Lancet · doi:10.1016/0140-6736(91)90133-a · Cited by 3,472
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 1×
“Within the male population a potential target for D-chiro-Ins administration might be elderly men suffering from late-onset hypogonadism (LOH), who present with an impaired production of adequate levels of testosterone by testis and sperm cells, resulting in androgen deficiency [142,143].”
BackgroundSneddon, J., Densem, J. W., Wald, N. J., Frost, C., Stone, R., & Gnant, M. (1991) · PubMed · Cited by 1,812
The causes of reduced fertility with cryopreserved semen
Watson, P. F. (2000) · Animal Reproduction Science · doi:10.1016/s0378-4320(00)00099-3 · Cited by 1,553
Sambuy, Y., De Angelis, I., Ranaldi, G., Scarino, M. L., Stammati, A., & Zucco, F. (2005) · Cell Biology and Toxicology · doi:10.1007/s10565-005-0085-6 · Cited by 1,488 · cited 1×
“discovered that, in presence of α-LA, myo-Ins increased its passage across the Caco-2 cell monolayer, used as a standard in vitro model of intestinal epithelium [182].”
Background
Research works printed but not linked: 2
- Maquenne L. Préparation, proprietés et constitution se l’inosite CR Hebd. Séance Acad. Sci. Paris 1887 104 225 227
- Montanino Oliva M. D-Chiro-Inositol, vitamin D and epigallocatechin gallate avoid surgery in women with uterine fibroids: 2 case reports Eur. Med. J. 2021 9 95 101
Cited by
Items 101–162 of 162
Nuclear magnetic resonance-based metabolomics in goat ovarian follicular fluid
Arcce, I. M. L., Silva, L. M. A., Canuto, K. M., Filho, E. D. G. A., de Sousa, F. C., Melo, L. M., Chaves, M. S., van Tilburg, M. F., & Freitas, V. J. D. F. (2023) · Small Ruminant Research · doi:10.1016/j.smallrumres.2023.106968 · Cited by 1
Sharma, N., & Vuppu, S. (2023) · Environmental Monitoring and Assessment · doi:10.1007/s10661-023-11857-8 · Cited by 2
“The molecular weight of inositol is 180.16 KDa, and it can be found in phospholipids and plasma lipoproteins (Dinicola et al., 2021).”
BackgroundInfluentialLyashenko, E. N., Kosolapova, N. V., & Saenko, Y. S. (2023) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush202323062120 · Cited by 1
The role of inositol in improving fertility in patients with PCOS
Turek, K., Gregułą, A., Stachyrak, K., Mika, D., Kłos, A., Mazur, B., Lambach, M., Pawlicki, M., Mazurek, A., & Wilanowska, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.57.009 · Cited by 1
Ricottini, L., Basciani, S., Spizzichini, M. L., Mattia, D. D., Noci, M. C.-I. D., Sorrentino, S., & Nordio, M. (2024) · Nutrients · doi:10.3390/nu16233977 · Cited by 1
Self-citationManoel, E. A., Vasconcelos, M. G., Freire, D. M. G., & Simas, A. B. C. (2025) · ChemistrySelect · doi:10.1002/slct.202405535 · Cited by 1
Çetin, M., Özek, G., Yur, S., Yaylacı, Ö. K., & Özek, T. (2025) · Records of Natural Products · doi:10.25135/rnp.2509.3644 · Cited by 2
The reliability of biomedical science: A case history of a maturing experimental field
Michell, R. H. (2022) · BioEssays · doi:10.1002/bies.202200020 · Cited by 1
“recent review article on inositols that was co-authored by no less than 40 geographically scattered EGOI members[76] stated that every one of them had ‘agreed to’ all of it.”
BackgroundMyo-inositol for subclinical hypothyroidism and potential prevention of thyroid tumors
Barbaro, D., Porcaro, G., & Benvenga, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00010-8 · Cited by 1
Self-citationInositols as adjuvant treatments in oncology
Bizzarri, M., Vučenik, I., & Appetecchia, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00007-8 · Cited by 1
Self-citationOptimization of surgical treatment of uterine myoma in women with obesity and the metabolic syndrome
Косей, Н. В., Татарчук, Т. Ф., Plaksiieva, K. D., Dubossarska, Y. O., Tokar, H. A., & Kozlov, O. S. (2023) · Reproductive Endocrinology · doi:10.18370/2309-4117.2023.67.40-46 · Cited by 2
Caruana, R., Zizzo, M. G., Caldara, G., Montalbano, F., Fasciano, S., Arena, D., Salamone, M., Fazio, G. D., Bottino, A., & Licciardi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073852 · Cited by 1
“The use of inositol(s) isomers in the management of polycystic ovary syndrome has a relevant clinical impact [19,20].”
BackgroundD-Chiro-inositol in PCOS: the myths and what we know about the reality
Unfer, V. (2022) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2022.2089638 · Cited by 2
Self-citationUPDATES ON GESTATIONAL DIABETES
Machado, L. F., Belon, M. D., & da Silva, T. R. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592722217112
Effectiveness of Myo- and d-chiro-inositol in the treatment of metabolic disorders
Diamanti‐Kandarakis, E., Papalou, O., & Soulage, C. O. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00005-4
Self-citationTreatments with inositols in IVF procedures
Espinola, M. S. B., Wdowiak, A., & Yu, T. C. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00015-7
Self-citationInositol and herbal substances as elements of complementary therapy in patients with PCOS
Aab, A., Zarańska, J., Kędra, K., MICHALIK, I., Bielak, M., & Zarański, B. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.16.01.012 · Cited by 1
“At the same time, it has been proven that the use of myo-inositol or its isomers brings significant clinical benefits in conditions such as PCOS, certain cancers, respiratory failure syndrome, and neurological or metabolic disorders [38].”
BackgroundAKBERBEYOVA, S. A., & MELIKGASIMOVA, N. A. (2023) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2023.05.18
current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
Lipińska, J., Kowalczuk, M., Lipiński, Ł., Kopeć, I., Kamiński, J., Klimczak, K., Loryś, L., Narloch, M., Kasprzak, S., & Kasprzak, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.59.011 · Cited by 2
Younis, R., Abbas, A., & Kalsoom, M. (2024) · doi:10.53555/jptcp.v31i3.4938
Zakovryashin, E. A., Russian Federation Moscow, Korneeva, I., Mityurina, E. V., & Сергеевна, С. Е. (2024) · Women s Health and Reproduction · doi:10.31550/2712-8598-2024-2-8-zhzir
Rehabilitation of patients after surgical treatment of polycystic ovary syndrome
Солопова, А. Г., Зайцева, О. В., Blinov, D. V., Ачкасов, Е. Е., & Константинович, Б. Г. (2024) · Vrach · doi:10.29296/25877305-2024-05-02
INOSITOL NO TRATAMENTO DA SÍNDROME DOS OVÁRIOS POLICÍSTICOS: AVALIAÇÃO DA EFICÁCIA
Rossato, D. G., Banhos, I. O., Marangoni, M. M., Maciel, M. G. D., & Nunes, Y. T. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i9.5649
Rehabilitation of patients after surgical treatment for polycystic ovary syndrome
Zaitseva, О. A., & Солопова, А. Г. (2024) · Реабилитология. · doi:10.17749/2949-5873/rehabil.2024.17 · Cited by 1
Громова, О. А., Torshin, I. Y., & Картлосовна, Т. Н. (2025) · Medical alphabet · doi:10.33667/2078-5631-2025-7-51-60
Basciani, S., Nordio, M., Spizzichini, M. L., & Gnessi, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1399308 · Cited by 3
“As such, physicians use this molecule to treat insulin dysfunctions in a panel of conditions characterized by metabolic abnormalities (18).”
Self-citationDíaz, N. Y. G., Reyes, B. T., & Cabrera, G. B. (2025) · South Florida Journal of Development · doi:10.46932/sfjdv6n6-061
Polycystic ovary syndrome: new trends in diagnosis and treatment
Абусуевна, А. З., Лукмановна, С. К., Efendieva, R. M., Амлетовна, С. Н., & Ibragimov, B. (2025) · Translational Medicine · doi:10.18705/2311-4495-2025-12-2-161-170
Albadri, H. M. B., Alrubaye, Y. S., & Abdulamir, H. A. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1764904
Dasgupta, S., Kumar, P., Biswas, P. K., Kamat, J., Ahire, P., Fatima, K., Hadwale, A., Nadkarni, S., Narvekar, P., Gaitonde, V., et al. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20253506
Elliott, D. M., Bayes, J., & Schloss, J. M. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200354
Громова, О. А., Torshin, I. Y., & Tapilskaya, N. I. (2025) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2025.687
Ганцгорн, Е. В., Максимов, М. Л., Kechkina, V. D., Rashkova, E. V., Колесникова, Н. А., & Безбородова, Е. Д. (2025) · Фармакология & Фармакотерапия · doi:10.46393/27132129_2025_4_32-38
Additional file 1 of Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W.-H., Li, L., Yang, D. C. H., Hsu, S.-W., Kenyon, N. J., & Chen, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26589909
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyírády, P., Ács, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601932
Fertility Treatment Options: Solving the Rubik’s Cube
Mellembakken, J. R. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010018
Özay, A. C., Özay, Ö. E., Edebal, O. H., Özay, Y., Oliva, M. M., Dinicola, S., & Unfer, V. (2025) · Journal of Pregnancy · doi:10.1155/jp/8816154
“In a comprehensive review, MI supplementation, which is started in the early weeks of pregnancy, will also prevent the onset of GDM [27].”
Self-citationExploring non -coding RNAs contribution to neural tube defects
Jameel, Z. I. (2026) · Human Gene · doi:10.1016/j.humgen.2025.201528
Xing, R., Jiang, L., Zhang, J., Zuo, X.-Q., Xu, X., Xue, M.-C., Zhao, Y.-R., & Hao, G. M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1746912
Antonowski, T., Osowski, A., & Wojtkiewicz, J. (2026) · Antioxidants · doi:10.3390/antiox15030297
Giani, C., Russo, M., Lapi, P., Profilo, M. A., Forleo, R., Mazzi, B., Ghirri, A., Caresia, L., Campennì, A., Durante, C., et al. (2026) · Life · doi:10.3390/life16030391
“According to the literature, a 4 g dose of MI shows significant clinical efficacy across different pathological conditions [35,36].”
Self-citationKorai, A., Baba, T., Kasuga-Yamashita, F., Nagao, S., Fujibe, Y., 森下, 美., Kuno, Y., Mariya, T., Ikeda, K., Honnma, H., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346159 · Cited by 1
“The MI/DCI ratio in follicular fluid is 100:1 in healthy individuals, it decreases to 0.2:1 in insulin-resistant PCOS patients [12].”
InfluentialDruzhinina, A. A., Gyulakhmedova, S. M., Alyautdina, O. S., Bashokouh, F., Eliseeva, E. M., & Chistokhina, A. A. (2026) · Avicenna Bulletin · doi:10.25005/2074-0581-2026-28-1-122-139
“Insulin secondary messengers bind to and allosterically ac - tivate Mg2⁺-dependent protein phosphatases in the cytosol and mitochondria, thereby increasing glycogen levels in the liver and skeletal muscles [19].”
Guo, X., Xu, M., Liu, L., Lin, Q., Gao, R., Xu, R., Wei, Y., Liang, Z., Wu, P., Dong, Z., et al. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108980
Nawathe, V. A., Verma, S., Pal, A., Pawar, D., & Sharma, A. (2026) · Cureus · doi:10.7759/cureus.108032 · Cited by 1
Lorenzo, C. D., Nordio, M., Brongo, F., Casillo, F., Basciani, S., Sebastianelli, G., Serrao, M., Lorenzo, G. D., & Coppola, G. (2026) · Nutrients · doi:10.3390/nu18101554
“…including FSH, TSH, and insulin), and as a component of structural lipids like phosphatidyl-inositol and its various phosphate lipid derivatives [52]; moreover, it has been shown to have a vital antioxidant effect [53–55], further characterizing this molecule as a multifunctional compound…”
Self-citationLinares, R., Rosas, G., Vieyra, E., Chaparro, A., Espinoza, J. A., Ramírez, D. A., Silva, C., Rosas, P., Macías, V.-M., & Morales‐Ledesma, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114715 · Cited by 1
“MI is also part of membrane phosphatidylinositols, precursors of second messengers such as inositol triphosphate (IP3) and diacylglycerol (DAG), which regulate various hormonal activities, including the action of insulin, FSH and thyroid-stimulating hormone (TSH) [210,216].”
Rusni, S., Yoshioka, Y., Pratiwi, H. M., Takagi, T., Royan, M. R., Hojo, Y., Uno, S., Kanda, S., Takehana, Y., Kinoshita, M., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202502623r
Effect of Myo-Inositol Supplementation in Polycystic Ovary Syndrome—Scoping Review
Habryka, J., Ławniczek, M., & Krupa, S. (2026) · Nutrients · doi:10.3390/nu18132093 · Cited by 1
“This heterogeneity is manifested in differences in supplementation protocols, where the doses of MI, DCI and their proportions are variable, as well as the combinations used with other active substances, such as ALA or melatonin [22,27].”
Ortiz, A. Y. T., Ariza‐Ortega, J. A., Zafra‐Rojas, Q. Y., & Ramírez‐Moreno, E. (2026) · Vida Científica Boletín Científico de la Escuela Preparatoria No 4 · doi:10.29057/prepa4.v14i28.16850
Liu, A.-B., Shen, Y., Yang, L., Ma, L., & Zhang, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1820625 · Cited by 1
“Myo-inositol and its derivatives play key roles in various biological processes, including glucose metabolism, cell signaling, gene transcription, and apoptosis (Dinicola et al., 2021).”
Combination therapy of hypogonadism: the outcomes of Inokirol® administration in its composition
Gamidov, S. I., Popova, A. Y., Валерьевич, Ш. Т., & Guluzade, K. S. (2026) · Urology Herald · doi:10.21886/2308-6424-2026-14-2-28-38
The role of inositol in reproductive health
Sokolova, L. K., & Belchina, Y. B. (2025) · Reproductive Endocrinology · doi:10.18370/2309-4117.2025.81.35-42
Singla, J., Yadav, S., & Gayen, J. R. (2026) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2026.104943 · Cited by 1
Fossatti, G. D. C. C., & Quintero-Montenegro, R. I. (2026) · Beverages · doi:10.3390/beverages12080093
“Furthermore, inositol phosphates, particularly inositol hexakisphosphate (IP6), have been shown to modulate energy metabolism and improve glucose homeostasis [17–19].”
Özdem, B., Kaymaz, T., Yıldırım, I., & Demir, C. (2026) · Applied Biological Chemistry · doi:10.1186/s13765-026-01124-y
“It makes intracellular calcium (Ca + 2 ) concentration control [5], cell membrane potential maintenance [6], gene expression modulation [7], insulin signal transduction [8–10], contributes to reproduction [11], and modulates ovarian steroidogenesis [12, 13].”
Gázquez, A., Origüela, V., Prieto‐Sánchez, M. T., Blanco‐Carnero, J. E., & Larqué, E. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110514
Cardozo, L. L. Y., Eissa, M., Basnet, J., Thompson, K., & Romero, D. G. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.10.006
Орлова, С. В., & Никитина, Е. А. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-22-37-42
Myo-inositol in placental metabolism and function: Implications for gestational diabetes mellitus
Salehpour, S., Hosseini, S., Zarisfi, Z., & Rezaei, M. (2026) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2025.10.020
Nordio, M., Basciani, S., Bilotta, G., & Aragona, C. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/6767158
Self-citationFacchinetti, F., Garzon, S., & Rađenović, S. S. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112241
Self-citation
Metadata
- Authors
- Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., Benvenga, S., Stringaro, A., Barbaro, D., Appetecchia, M., Aragona, C., Bezerra Espinola, M. S., Cantelmi, T., Cavalli, P., Chiu, T. T., Copp, A. J., D’Anna, R., Dewailly, D., Di Lorenzo, C., Diamanti-Kandarakis, E., Hernández Marín, I., Hod, M., Kamenov, Z., Kandaraki, E., Monastra, G., Montanino Oliva, M., Nestler, J. E., Nordio, M., Ozay, A. C., Papalou, O., Porcaro, G., Prapas, N., Roseff, S., Vazquez-Levin, M., Vucenik, I., & Wdowiak, A.
- Affiliations
- Systems Biology Group Lab, 00161 Rome, Italy
- University of Modena and Reggio Emilia (IT)
- Lyon 1 Université (FR)
- University College London (GB)
- Sapienza University of Rome (IT)
- University of Insubria (IT)
- National University of Singapore (SG)
- Zhordania and Khomasuridze Institute of Reproductology, Tbilisi 0112, Georgia
- University of Messina (IT)
- Istituto Superiore di Sanità (IT)
- Ospedale di Livorno (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- Institute for Interpersonal Cognitive Therapy, 00100 Rome, Italy
- IRCCS Humanitas Research Hospital (IT)
- IVF Centre, Hong Kong 999077, China
- Université de Lille (FR)
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, 04100 Latina, Italy
- Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, 15123 Athens, Greece
- Human Reproduction Department, Hospital Juárez de México, Universidad Nacional Autónoma de México (UNAM), Mexico City 07760, Mexico
- Tel Aviv University (IL)
- Medical University of Sofia (BG)
- Hygeia Hospital (GR)
- Department of Obstetrics and Gynecology, Santo Spirito Hospital, 00193 Rome, Italy
- Virginia Commonwealth University (US)
- A.S.L. RMF, 00053 Civitavecchia, Italy
- Department of Obstetrics and Gynecology, Near East University Hospital, Nicosia 99138, Cyprus
- Azienda Unità Sanitaria Locale Umbria n. 2 (IT)
- Iakentro (GR)
- Reproductive Endocrinology and Infertility, South Florida Institute for Reproductive Medicine (IVFMD), Boca Raton, FL 33458, USA
- Instituto de Biología y Medicina Experimental (IBYME, CONICET-FIBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET), Buenos Aires 2490, Argentina
- Department of Medical & Research Technology and Pathology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
- Medical University of Lublin (PL)
- Corresponding author
- Facchinetti, Fabio
- ORCID
- Dinicola, Simona
- Unfer, Vittorio
- Facchinetti, Fabio
- Soulage, Christophe O.
- Greene, Nicholas D.
- Bizzarri, Mariano
- Laganà, Antonio Simone
- Chan, Shiao-Yng
- Bevilacqua, Arturo
- Pkhaladze, Lali
- Benvenga, Salvatore
- Stringaro, Annarita
- Barbaro, Daniele
- Appetecchia, Marialuisa
- Cavalli, Pietro
- Copp, Andrew J.
- D’Anna, Rosario
- Dewailly, Didier
- Di Lorenzo, Cherubino
- Diamanti-Kandarakis, Evanthia
- Kamenov, Zdravko
- Kandaraki, Eleni
- Monastra, Giovanni
- Nordio, Maurizio
- Ozay, Ali C.
- Papalou, Olga
- Roseff, Scott
- Wdowiak, Artur
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-30
- Volume
- 22
- Issue
- 19
- Pages
- 10575
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508595
- OpenAlex
- W3203286644
- Cited by
- 154
- References
- 201
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 29 · 2023: 43 · 2022: 27 · 2021: 1
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- National University of Singapore (submittedVersion, cc-by)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- Funders
- Action Medical Research
- Sparks (17ICH03)
- Medical Research Council (MR/T003847/1)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- myo-inositol, D-chiro-inositol, steroidogenesis, aromatase, testosterone production, polycystic ovary syndrome, gestational diabetes mellitus, male fertility, sperm abnormalities, insulin sensitizers, inositol supplementation
- MeSH terms
- Female, Humans, Inositol, Polycystic Ovary Syndrome, Pregnancy, Testosterone, Theca Cells, Molecular Structure, Signal Transduction, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.